{
    "nct_id": "NCT06073821",
    "official_title": "A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia",
    "inclusion_criteria": "* Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment\n* Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2\n* Measurable disease by Computer Tomography/Magnetic Resonance Imaging\n* Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin < 3.0 x ULN\n* Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous systemic treatment for CLL\n* Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation\n* Known central nervous system involvement\n* History of confirmed progressive multifocal leukoencephalopathy (PML)\n* Uncontrolled hypertension\n\nNote: Other protocol defined criteria may apply",
    "miscellaneous_criteria": ""
}